secwatch.observer — SEC 8-K summary
======================================

Issuer:     C4 Therapeutics, Inc. (CCCC)
CIK:        0001662579
Form:       8-K
Filed at:   2023-02-23T23:59:59+00:00
Accession:  0001662579-23-000040
Event type: earnings
Sentiment:  negative
Materiality: 0.90
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

C4 Therapeutics Reports Q4 and Full Year 2022 Financial Results with Net Loss of $128.2M and Cash Runway to End of 2024
--------------------------------------------------------------------------------

- Revenue for 2022 was $31.1M, down from $45.8M in 2021, primarily due to one-time recognition in prior year from Roche agreement termination.
- Net loss for 2022 was $128.2M ($2.62 per share) compared to $83.9M ($1.82 per share) in 2021, driven by increased R&D and G&A expenses.
- Cash, cash equivalents and marketable securities totaled $337.1M as of Dec 31, 2022, expected to fund operations through end of 2024.
- Phase 1 dose escalation data for CFT7455 (multiple myeloma) and CFT8634 (synovial sarcoma) expected in second half of 2023.
- IND submission for CFT8919 (EGFR L858R degrader) on track for first half of 2023; CFT1946 Phase 1/2 trial dosing first patient in January 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1662579/000166257923000040/0001662579-23-000040-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1662579/000166257923000040/cccc-20230223.htm
  HTML page:      https://secwatch.observer/filing/0001662579-23-000040

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer